Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month fo ...

The end of the classic Control Panel is approaching. In the Windows Insider previews, Microsoft is now shifting more to the settings.

Total revenue of $25.7 million, up 6% sequentially 4 licensing deals signed for NeuPro NPUs, marking pivotal moment for Ceva's AI business 2 strategic automotive IP agreements secured ...

Durability remains a top priority for customers. Today’s grand touring technology helps evenly distribute pressure across the ...